148 related articles for article (PubMed ID: 10630354)
1. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.
Blay JY; Judson I; Rodenhuis S; Hermans C; Smith M; van Glabbeke M; Verweij J
Anticancer Drugs; 1999 Nov; 10(10):873-7. PubMed ID: 10630354
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
[TBL] [Abstract][Full Text] [Related]
3. Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer.
Botwood N; James R; Vernon C; Price P
Ann Oncol; 2000 Aug; 11(8):1023-8. PubMed ID: 11038040
[TBL] [Abstract][Full Text] [Related]
4. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer.
Manegold C; Buchholz E; Kloeppel R; Kreisel C; Smith M
Lung Cancer; 2002 May; 36(2):183-9. PubMed ID: 11955653
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
[TBL] [Abstract][Full Text] [Related]
9. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.
Feliu J; Mel JR; Camps C; Escudero P; Aparicio J; Menéndez D; García Girón C; Rodriguez MR; Sánchez JJ; González Barón M;
Eur J Cancer; 2002 Jun; 38(9):1204-11. PubMed ID: 12044507
[TBL] [Abstract][Full Text] [Related]
10. Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck.
Clarke SJ; Zalcberg J; Olver I; Mitchell PL; Rischin D; Dalley D; Green M; Davidson YE
Ann Oncol; 2000 Feb; 11(2):239-41. PubMed ID: 10761765
[TBL] [Abstract][Full Text] [Related]
11. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study.
Valentini V; Doglietto GB; Morganti AG; Turriziani A; Smaniotto D; De Santis M; Ratto C; Sofo L; Cellini N
Eur J Cancer; 2001 Nov; 37(16):2050-5. PubMed ID: 11597383
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of Raltitrexed ('Tomudex') in elderly patients with colorectal cancer.
Romiti A; Tonini G; Santini D; Di Seri M; Masciangelo R; Mezi S; Verì A; Santuari L; Vincenzi B; Brescia A; Marchei P; Frati L; Tomao S
Anticancer Res; 2002; 22(5):3071-6. PubMed ID: 12530045
[TBL] [Abstract][Full Text] [Related]
14. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
Zalcberg J
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
16. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.
François E; Hebbar M; Bennouna J; Mayeur D; Perrier H; Dorval E; Martin C; Bourgeois H; Barthélemy P; Douillard JY
Oncology; 2005; 68(4-6):299-305. PubMed ID: 16020956
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
De Pas T; Curigliano G; Masci G; Catania C; Comandone A; Boni C; Tucci A; Pagani O; Marrocco E; de Braud F;
Ann Oncol; 2002 Jan; 13(1):161-6. PubMed ID: 11863099
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
